Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04925284 · ClinicalTrials.gov registry record · Phase 1
Study of XB002 in Subjects With Solid Tumors (JEWEL-101)
A Phase 1 study of Non-Small Cell Lung Cancer and Pancreatic Cancer, sponsored by Exelixis.
- Completed
- Registry status
- Phase 1
- Development phase
- 269
- Enrollment target
- 20
- Study locations
NCT04925284 is a Phase 1 study of Non-Small Cell Lung Cancer and Pancreatic Cancer that has completed, run by Exelixis. The registered enrollment target is 269 participants, below the 658-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (59% lower). The trial reports 20 study locations across 14 states.
The verdict
NCT04925284, a Phase 1 study of Non-Small Cell Lung Cancer and Pancreatic Cancer, has completed, sponsored by Exelixis.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 269 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 1, open-label, multicenter, dose-escalation and expansion study evaluating the safety, tolerability, PK, pharmacodynamics, and clinical antitumor activity of XB002 administered IV q3w alone and in combination with nivolumab or bevacizumab to subjects with advanced solid tumors.
Conditions Studied
Interventions
- DRUG Bevacizumab
- DRUG Nivolumab
- DRUG XB002
Study Locations (20)
California
- Exelixis Clinical Site#59 - Fountain Valley
- Exelixis Clinical Site #21 - Los Angeles
- Exelixis Clinical Site #26 - Los Angeles
Arizona
- Exelixis Clinical Site #20 - Tucson
- Exelixis Clinical Site#95 - Tucson
Maryland
- Exelixis Clinical Site #6 - Baltimore
- Exelixis Clinical Site #18 - Columbia
Michigan
- Exelixis Clinical Site #19 - Detroit
- Exelixis Clinical Site #10 - Detroit
New Jersey
- Exelixis Clinical Site #8 - East Brunswick
- Exelixis Clinical Site #7 - New Brunswick
Alabama
- Exelixis Clinical Site #48 - Birmingham
Arkansas
- Exelixis Clinical Site#58 - Little Rock
Connecticut
- Exelixis Clinical Site #16 - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 269 participants |
| Start Date | 2021-06-07 |
| Est. Completion | 2025-03-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04925284
The ClinicalTrials.gov registry entry for NCT04925284 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 269 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 658-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (59% lower). The listed sponsor is Exelixis, which has 48 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 3 interventions - of which Bevacizumab is the first listed.
NCT04925284 reports 20 study locations spanning 14 distinct geographic areas - top geographies include California, Arizona, Maryland.
Frequently Asked Questions
What is clinical trial NCT04925284 about?
NCT04925284 is a clinical study titled "Study of XB002 in Subjects With Solid Tumors (JEWEL-101)". This is a Phase 1, open-label, multicenter, dose-escalation and expansion study evaluating the safety, tolerability, PK, pharmacodynamics, and clinical antitumor activity of XB002 administered IV q3w alone and in combination with nivolumab or bevacizumab to subjects with advanced solid tumors.
What is the current status of trial NCT04925284?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 269 participants. The study started on 2021-06-07. Estimated completion is 2025-03-10.
What conditions does trial NCT04925284 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Pancreatic Cancer, Endometrial Cancer, Cervical Cancer, Triple Negative Breast Cancer.
What interventions are being tested in trial NCT04925284?
The interventions under investigation include: Bevacizumab (DRUG), Nivolumab (DRUG), XB002 (DRUG).
Who is sponsoring clinical trial NCT04925284?
This trial is sponsored by Exelixis, which has 48 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04925284 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.